|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CDV3 |
Gene summary for CDV3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CDV3 | Gene ID | 55573 |
| Gene name | CDV3 homolog | |
| Gene Alias | H41 | |
| Cytomap | 3q22.1 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | Q9UKY7 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55573 | CDV3 | CA_HPV_1 | Human | Cervix | CC | 1.23e-13 | 2.66e-01 | 0.0264 |
| 55573 | CDV3 | CCII_1 | Human | Cervix | CC | 6.99e-08 | -5.25e-01 | 0.3249 |
| 55573 | CDV3 | sample1 | Human | Cervix | CC | 8.29e-14 | 6.41e-01 | 0.0959 |
| 55573 | CDV3 | L1 | Human | Cervix | CC | 2.45e-03 | -4.91e-02 | 0.0802 |
| 55573 | CDV3 | T1 | Human | Cervix | CC | 2.56e-18 | 5.60e-01 | 0.0918 |
| 55573 | CDV3 | HTA11_78_2000001011 | Human | Colorectum | AD | 3.00e-03 | 3.14e-01 | -0.1088 |
| 55573 | CDV3 | HTA11_347_2000001011 | Human | Colorectum | AD | 5.67e-13 | 3.15e-01 | -0.1954 |
| 55573 | CDV3 | HTA11_1391_2000001011 | Human | Colorectum | AD | 6.71e-10 | 5.17e-01 | -0.059 |
| 55573 | CDV3 | HTA11_6801_2000001011 | Human | Colorectum | SER | 9.31e-03 | 5.74e-01 | 0.0171 |
| 55573 | CDV3 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.48e-07 | 4.20e-01 | 0.294 |
| 55573 | CDV3 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 5.48e-03 | 7.56e-01 | 0.3487 |
| 55573 | CDV3 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 4.66e-05 | 3.91e-01 | 0.281 |
| 55573 | CDV3 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.53e-15 | 5.38e-01 | 0.3859 |
| 55573 | CDV3 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.65e-04 | 2.26e-01 | 0.3005 |
| 55573 | CDV3 | AEH-subject1 | Human | Endometrium | AEH | 1.11e-02 | 2.24e-01 | -0.3059 |
| 55573 | CDV3 | AEH-subject4 | Human | Endometrium | AEH | 2.50e-02 | 2.53e-01 | -0.2657 |
| 55573 | CDV3 | AEH-subject5 | Human | Endometrium | AEH | 4.92e-05 | 3.13e-01 | -0.2953 |
| 55573 | CDV3 | EEC-subject3 | Human | Endometrium | EEC | 5.97e-17 | 4.47e-01 | -0.2525 |
| 55573 | CDV3 | GSM5276934 | Human | Endometrium | EEC | 4.12e-14 | 4.43e-01 | -0.0913 |
| 55573 | CDV3 | GSM5276935 | Human | Endometrium | EEC | 1.63e-07 | 2.93e-01 | -0.123 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CDV3 | SNV | Missense_Mutation | novel | c.439G>A | p.Val147Ile | p.V147I | Q9UKY7 | protein_coding | deleterious(0.01) | benign(0.415) | TCGA-AJ-A3EK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CDV3 | SNV | Missense_Mutation | novel | c.616G>A | p.Glu206Lys | p.E206K | Q9UKY7 | protein_coding | tolerated(0.18) | possibly_damaging(0.757) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| CDV3 | insertion | In_Frame_Ins | novel | c.776_777insGTTTAAATTACAAATCAC | p.Ter259delinsTer | p.*259delins* | Q9UKY7 | protein_coding | TCGA-B5-A11I-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | PD | ||
| CDV3 | SNV | Missense_Mutation | novel | c.560C>A | p.Pro187Gln | p.P187Q | Q9UKY7 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-80-5608-01 | Lung | lung adenocarcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| CDV3 | SNV | Missense_Mutation | novel | c.574G>A | p.Asp192Asn | p.D192N | Q9UKY7 | protein_coding | deleterious(0.01) | probably_damaging(0.999) | TCGA-CN-A6V1-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Immunotherapy | erbitux | CR |
| CDV3 | deletion | Frame_Shift_Del | novel | c.591_592delCC | p.Leu198AlafsTer13 | p.L198Afs*13 | Q9UKY7 | protein_coding | TCGA-DJ-A13W-01 | Thyroid | thyroid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |